Dr Harsh Vardhan launches CSIR partnered clinical trials website on repurposed Covid drugs

CSIR is exploring multiple combination clinical trials of anti-virals with host-directed therapies for the potential treatment of COVID-19. CSIR is also working with the Ministry of AYUSH for clinical trials of AYUSH drugs and has undertaken safety & efficacy trials of AYUSH prophylactics and therapeutics based on individual plant-based compounds and in combination. Five clinical trials involving Withaniasomnifera, Tinosporacordifolia + Piper longum(in combination), Glycyrrhizaglabra, Tinosporacordifolia & Adhatodavasica (individually and in combination) and AYUSH-64 formulation are undergoing safety and efficacy trials.

A key clinical trial of CSIR is the Sepsivac (Mw) against COVID -19 in partnership with Cadila. The phase 2 clinical trial has been completed successfully on critically ill COVID-19 patients, and more extensive Phase 3 trial is on the anvil. Further, the Phase 2 trial of phytopharmaceutical AQCH on Covid-19 patients with Sun Pharma and DBT is underway.

In addition to clinical trials of repurposed drugs and vaccines, CSIR has been involved in clinical trials of diagnostics and devices.

Dr Harsh Vardhan emphasized that while the scientists are working on developing drugs and vaccines, as of now, social distancing, wearing masks and other precautions are essential and must be duly followed if we have to win the fight against COVID-19.

Dr. Shekhar C Mande, Secretary, DSIR and DG-CSIR, Dr.Ranjana Aggarwal, Dir, NISTADS and Dr. Geetha Vani Rayasam, Senior Principal Scientist & Head, Science Communication and Dissemination Directorate CSIR HQ, were present on the occasion. CSIR Directors, Heads of Departments, and Scientists involved in Clinical Trials joined the event virtually.